On November 6, Exelixis fell 5.03% in Regular Trading, trading at $69.1 per share, with turnover of $108 million.
The most recent company-specific developments were its late-October quarterly results and a same-day analyst target increase. Exelixis reported adjusted third-quarter EPS of $0.94 and revenue of $658.7 million, both above consensus expectations, while it guided full-year revenue to $2.50 billion to $2.55 billion, with the top end matching market estimates rather than exceeding them.
Separately, RBC raised its price target to $58 from $51 while maintaining a Sector Perform rating. Even so, the stock had recently traded above both that target and the broader analyst mean target of about $59.64, which limits the explanatory power of these items for the current decline.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments